<DOC>
	<DOCNO>NCT02333162</DOCNO>
	<brief_summary>This phase I trial study side effect best dose intensity modulate total marrow irradiation ( IMTMI ) give together fludarabine phosphate melphalan treat patient cancer blood ( hematologic ) return period improvement ( relapse ) undergo second donor stem cell transplant . IMTMI type radiation therapy bone marrow may less toxic may also reduce chance cancer return . Giving fludarabine phosphate , melphalan , IMTMI donor stem cell transplant may help stop growth cell bone marrow , include normal blood-forming cell ( stem cell ) cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Intensity Modulated Total Marrow Irradiation , Fludarabine Phosphate , Melphalan Treating Patients With Relapsed Hematologic Cancers Undergoing Second Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The determine maximum tolerate dose ( MTD ) intensity-modulate total marrow irradiation ( IMTMI ) combination fludarabine ( fludarabine phosphate ) /melphalan condition second allogeneic stem cell transplantation patient hematologic malignancy . SECONDARY OBJECTIVES : I . To determine overall toxicity day 100 transplant relate mortality second allogeneic hematopoietic stem cell transplantation condition increase dos intensity-modulate total marrow irradiation ( IMTMI ) combination fludarabine/melphalan . II . To determine time neutrophil platelet engraftment second allogeneic hematopoietic stem cell transplantation condition increase dos intensity-modulate total marrow irradiation ( IMTMI ) combination fludarabine/melphalan . III . To determine overall survival ( OS ) event-free-survival ( EFS ) patient hematologic undergoing second allogeneic hematopoietic stem cell transplant ( HSCT ) conditioning fludarabine/melphalan IMTMI . OUTLINE : This dose-escalation study IMTMI . CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute daily day -7 -3 melphalan IV day -2 . Patients also undergo IMTMI twice daily ( BID ) 2 5 day day -7 -3 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell transplant ( PBSCT ) bone marrow transplant ( BMT ) day 0 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive tacrolimus IV continuously 24 hour orally ( PO ) BID day -2 180 taper thereafter mycophenolate mofetil IV every 8 hour PO day 0-28 ( match donor ) day 0-40 ( alternative donor ) taper day 60 . After completion treatment , patient follow periodically 1 year yearly 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients follow disease : acute myeloid leukemia ( AML ) high risk myelodysplastic syndrome ( MDS ) undergo second allogeneic ( allo ) stem cell transplant ( SCT ) use donor different donor disease relapse ; patient hematologic malignancy , include acute lymphoblastic leukemia ( ALL ) , discretion investigator Karnofsky performance status 70 Life expectancy severely limited concomitant illness Adequate cardiac pulmonary function ; patient decrease left ventricular ejection fraction ( LVEF ) = &lt; 40 % diffusion capacity carbon monoxide ( DLCO ) = &lt; 50 % predict evaluated cardiology pulmonary prior enrollment protocol Serum creatinine = &lt; 1.5 mg/dL creatinine clearance &gt; 50 ml/min ; patient minor deviation may accept protocol discussion principal investigator ( PI ) Serum bilirubin = &lt; 2.0 mg/dl ; patient minor deviation may accept protocol discussion PI Serum glutamic oxaloacetic transaminase ( SGPT ) &lt; 5 x upper limit normal ; patient minor deviation may accept protocol discussion PI No evidence chronic active hepatitis cirrhosis Human immunodeficiency virus ( HIV ) negative Patient pregnant Patient guardian able sign inform consent DONOR : Since patient already first alloSCT ; majority time , match donor use second alloSCT ; patient multiple donor , alternative match ( 8/8 10/10 ) donor could use second alloSCT ; donor could match related donor match unrelated donor registry DONOR : If one potential volunteer unrelated donor consider suitable , selection suitable donor prioritize follow follow institutional guideline stem cell transplant standard operate procedure ( SOP ) : Age donor ( 1824 &gt; 2534 &gt; 3544 &gt; 45+ ) Sex donor ( male &gt; female , nulliparous female &gt; parous , multiparous female ) Cytomegalovirus ( CMV ) status , recipient CMV seronegative ( CMV &gt; CMV+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>